Cite
HARVARD Citation
Rao, A. et al. (2015). Phase II Study of Sorafenib and Bortezomib for First‐Line Treatment of Metastatic or Unresectable Renal Cell Carcinoma. Oncologist. pp. 370-371. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Rao, A. et al. (2015). Phase II Study of Sorafenib and Bortezomib for First‐Line Treatment of Metastatic or Unresectable Renal Cell Carcinoma. Oncologist. pp. 370-371. [Online].